PBAC Recommendation for molnupiravir (Lagevrio®) February 2022
Page last updated: 25 February 2022
The Pharmaceutical Benefits Advisory Committee (PBAC) undertook an expedited consideration of a sponsor submission to add molnupiravir (Lagevrio®) to the Pharmaceutical Benefits Scheme (PBS) for use in treating patients with mild to moderate COVID-19 who are at risk of developing severe disease requiring hospitalisation. The expedited consideration by PBAC recognises the urgent public health need related to the prevention, management, or treatment of SARS-CoV-2 infections. The PBAC recommended the listing on the PBS of molnupiravir as a General Schedule, Authority Required (Streamlined) benefit. The outcome of the PBAC consideration is available on the PBS website.